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Introduction
Ubiquitin (Ub) is a 76 amino acid protein regulator of a wide
variety of cellular processes, including proteolysis by the pro-
teasome, regulation of cell division, transcription regulation,
and DNA repair. Ub modifies protein substrates by forming an
isopeptide bond between the C-terminal carboxylate of Ub
and the e-amino moiety of a lysine side chain or the N termi-
nus of the target protein or Ub itself.[1] The conjugation of Ub
is brought about by the consecutive action of Ub ligases from
three classes, while Ub conjugates can be disassembled by any
of ~100 currently known deubiquitinating enzymes (DUBs)
that are encoded in the human genome. These DUBs belong
to five distinct classes: four established cysteine protease fami-
lies, and a class of metalloproteases.[2] The function of many
DUBs remains unclear at present, and the study of their func-
tion depends on the availability of suitable assay reagents.
Current activity-based probes that target DUBs are based on
the Ub sequence and are equipped with a reactive C-terminal
warhead, for example, vinyl methyl ester (VME), and an N-ter-
minal epitope tag (Figure 1A), and they react with the active
site cysteine residue that is present in most DUBs,[3] as shown
in Figure 1B. These probes can be used to visualize the activity
of multiple DUBs in a single experiment and they have proved
indispensable in the search for novel DUBs, including a novel
class of ovarian tumor (OTU)-domain-containing DUBs[3] and
DUBs encoded by pathogens such as the herpes virus,[4] api-
complexan parasites Toxoplasma gondii[5] and Plasmodium falci-
parum,[6] and the nematode Trichinella spiralis.[7] In addition,
with the Ub system arising as a novel pool of potential drug
targets,[8] Ub-based DUB probes have proven instrumental in
monitoring the potency and specificity of small-molecule DUB
inhibitors in competition experiments.[9] Current activity-based
probes are limited to those with the HA epitope tag, and the
classical preparation of DUB probes takes advantage of intein
chemistry to generate intermediate thioesters that are convert-
ed into active-site-directed probes and more recently into
probes with C-terminally extended isopeptide warheads.[10]
Intein chemistry tends to be laborious, the required thioesters
are frequently partially hydrolyzed, and the amount of material
that can be obtained is often limited. Secondly, intein-mediat-
ed expression and ligation methods are largely limited to
those amino acids that can be encoded genetically, although
Epitope-tagged active-site-directed probes are widely used to
visualize the activity of deubiquitinases (DUBs) in cell extracts,
to investigate the specificity and potency of small-molecule
DUB inhibitors, and to isolate and identify DUBs by mass spec-
trometry. With DUBs arising as novel potential drug targets,
probes are required that can be produced in sufficient
amounts and to meet the specific needs of a given experi-
ment. The established method for the generation of DUB
probes makes use of labor-intensive intein-based methods that
have inherent limitations concerning the incorporation of un-
natural amino acids and the amount of material that can be
obtained. Here, we describe the total chemical synthesis of
active-site-directed probes and their application to activity-
based profiling and identification of functional DUBs. This syn-
thetic methodology allowed the easy incorporation of desired
tags for specific applications, for example, fluorescent report-
ers, handles for immunoprecipitation or affinity pull-down, and
cleavable linkers. Additionally, the synthetic method can be
scaled up to provide significant amounts of probe. Fluorescent
ubiquitin probes allowed faster, in-gel detection of active
DUBs, as compared to (immuno)blotting procedures. A biotiny-
lated probe holding a photocleavable linker enabled the affini-
ty pull-down and subsequent mild, photorelease of DUBs. Also,
DUB activity levels were monitored in response to overexpres-
sion or knockdown, and to inhibition by small molecules. Fur-
thermore, fluorescent probes revealed differential DUB activity
profiles in a panel of lung and prostate cancer cells.
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recent advances have been made that allow the modification
of the Ub sequence by using biological genetic code expan-
sion methods.[11] Synthetic methods can overcome these limita-
tions. We recently reported the total linear synthesis of Ub,[12]
thereby allowing convenient control over additional residues
that can be incorporated. This synthetic route can be scaled
up to generate larger amounts of material than is feasible
when using intein-based techniques.
Here, we describe how linear Ub synthesis can be used to
devise new Ub-based activity probes by decorating the Ub
N terminus with dyes, affinity handles (epitope tag, biotin),
spacers, and cleavable linkers, while selectively adding a C-ter-
minal active-site directed moiety (Figure 1A). We demonstrate
the value of these probes in activity-profiling experiments and
the assessment of small-molecule DUB inhibitor specificities.
Furthermore, we show that the installation of pull-down han-
dles and selectively cleavable linkers facilitates isolation and
DUB release procedures.
Results and Discussion
Linear chemical synthesis of active-site-directed ubiquitin-
based probes
We based the synthetic route towards novel UbVME probes on
the linear solid-supported total synthesis of Ub that we report-
ed recently,[12] which makes use of four pseudoproline building
blocks and two dimethoxybenzyl (Dmb) dipeptides to prevent
folding and/or aggregation of the growing peptide chain on-
resin. In that study, we reported that a minimum of four of
these building blocks was required for a synthesis that was suf-
ficiently productive. A recent report claimed, without further
experimental evidence, to have further optimized linear Ub
synthesis by using only two of these building blocks.[13] How-
ever, a careful comparison (Figure S1 in the Supporting Infor-
mation) confirms that the use of six such building blocks pro-
vides Ub products of superior quality, as we reported previous-
ly.[12]
We first focused on the total chemical synthesis of the classi-
cal epitope-tagged DUB probe HAUbVME, previously generat-
ed by intein chemistry,[3] as a benchmark. Our synthetic ap-
proach towards HA-tagged UbVME 1 (Figure 1C) is outlined in
Figure 1D (Method A). The Ub(1–75) sequence (C-terminal Gly
residue omitted) was built up on a hyper-acid-labile trityl resin.
Subsequently, two 6-amino hexanoic acid (Ahx) residues and
the amino acids of the HA-tag (YPYDVPDYA) were sequentially
introduced to the N terminus of the side-chain-protected,
resin-bound peptide. The Ahx residues were incorporated to
favor accessibility to anti-HA antibody. After mild acidic cleav-
age from the resin, glycine vinyl methyl ester (GlyVME) was
coupled to the free C terminus of the partially protected pep-
tide in solution. Subsequent deprotection and HPLC purifica-
tion afforded HA-tagged UbVME 1 in 16% overall yield follow-
ing purification. To evaluate application of chemically synthe-
sized HA-tagged UbVME 1, EL4 cell lysate was incubated with
either the classical HA-tagged probe (prepared by intein
chemistry) or synthetic probe 1, and DUB activity was visual-
ized by immunoblotting (Figure 2A). Identical labeling profiles
were observed, thus showing that chemically synthesized
probes can be successfully used to label DUBs.
We then turned our attention to the generation of a probe
holding a fluorophore to allow direct in-gel fluorescence scan-
ning. Fluorescence imaging is not only faster than classical im-
munoblotting techniques, it also circumvents unspecific back-
Figure 1. A) Classical DUB probes versus chemically synthesized probes. B) Ub-based probes react with the active-site cysteine residue present in most DUBs.
C) Table of probes synthesized via the two reaction pathways. See Figure S2 for structures of incorporated tags and linkers. D) Synthesis scheme: two reaction
pathways to chemically synthesize active-site-directed Ub-based probes i) 1. PyBOP, DIPEA, R-COOH, NMP, 16 h, RT; 2. Piperidine, NMP, 310 min., RT; ii) HFIP/
DCM, 30 min, RT; iii) PyBOP, Et3N, GlyVME, DCM, 16 h, RT; iv) TFA, TIPS, H2O, 3 h, RT; v) PyBOP, DIPEA, TMR, DCM, 16 h, RT. PG=protecting group.
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ground labeling due to cross-reactivity of the antibodies used
for immunoblotting. Following condensation of GlyVME at the
C terminus, the fluorophore 5-carboxytetramethylrhodamine
(TMR) was introduced at the N terminus of the Ub-based
probe (Method B, Figure 1D). Removal of protective groups
followed by purification yielded probe 2 (Figure 1C) in 11%
overall yield following purification. The synthetic methodology
shown in Figure 1D conveniently allowed incorporation of
a range of single or multiple handles, including other fluoro-
phores such as Cy5 in probes 3 and 4, pull-down handles such
as a hexahistidine tag in probe 3, biotin in probes 4 and 5, and
a photocleavable linker in probe 5 (Figure 1C). Total yields of
10–20% following purification were obtained for the synthesis
of these UbVME probes after synthesis and HPLC purification.
Liquid chromatography profiles and mass spectrometric char-
acterizations of probes 1–5 are shown in Figures S3–S9.
Fluorescent UbVME probe allows fast detection of DUBs in
cell lysate
To investigate whether probe 2 can be used to profile DUB ac-
tivity with similar sensitivity and detection limits as the classical
probe HAUbVME, EL4 cell lysate was assayed with increasing
probe concentrations (Figure 2A and B). Labeled DUBs were vi-
sualized either by in-gel fluorescence (Figure 2B), or by chemi-
lumiscence following immunoblotting (Figure 2A). Similar DUB
labeling patterns were observed for probe 2 and HA-tagged
UbVME, and labeling with the probes was dose-dependent
(Figure 2A and B). Labeling of DUBs in cell lysate with probe 2
allowed direct in-gel fluorescence scanning, thereby resulting
in a much faster analysis than with immunoblotting tech-
niques. Furthermore, probe 2 appeared slightly more sensitive,
and revealed a few less-abundant or less-active DUBs that
were not easily revealed by HA-tagged UbVME. In addition,
with probe 2 a clearer picture was obtained, and bands could
be distinguished with higher resolution, likely because of the
direct nature of the readout. When near-infrared fluorescent
secondary antibodies were used, higher resolution pictures
were obtained (Figure S10A), compared to visualization by
chemiluminescence (Figure 2A). Still, superior pictures for la-
beled cell lysate were obtained by using fluorescent probe 2
(Figures 2B and S10B).
Biotin-tagged dual-activity probes for labeling and affinity
pull-down of proteins
Having shown that N-terminal tags can be introduced onto
UbVME probes without significantly changing DUB labeling
patterns, two tandem-tagged activity probes were designed
by combining a biotin-tag (to allow affinity pull-down of la-
beled DUBs) with either a fluorophore (for fluorescence imag-
ing, probe 4) or a photocleavable moiety (for catch-and-photo-
release purposes; probe 5). To investigate whether the biotin
tag of probe 4, when bound to a DUB, was accessible for cap-
ture by streptavidin, DUBs present in EL4 lysate were labeled
with probe 4 and visualized by either in-gel fluorescence scan-
ning or by western blotting (Figure S11). Congruent DUB label-
ing patterns were observed with both visualization methods,
thus showing that a biotin-tagged DUB-activity probe can be
used to pull down DUBs from cell extracts. In a next step, the
catch-and-photorelease principle was evaluated by the immo-
bilization of recombinant UCHL3 (a 26 kDa protein) labeled
with probe 5. Loaded neutravidin resin was exposed to UV
light, and input, flow through, and UV-elution samples were
analyzed by SDS-PAGE (Figure 3). UCHL3 labeled with probe 5
yielded an additional band that migrated at approximately
38 kDa. Coomassie staining and blotting with streptavidin–
poly-HRP verified biotinylation of UCHL3 by labeling with
probe 5 (“input” lanes, Figure 3). Coomassie staining showed
that the UV-elution sample contained UCHL3:probe conjugate
(Figure 3, left), while the absence of a biotin tag (Figure 3,
right) verified the catch-and-photorelease principle.
Assessment of DUB inhibitor potency by using a fluorescent
UbVME probe
Ub-based probe competition experiments have recently been
reported in the assessment of DUB inhibitor potency by using
HA-tagged probe.[9] As fluorescent probe 2 allows rapid in-gel
detection of DUBs, DUB inhibitor profiles can be obtained now
in a more high-thoughput manner. To test whether fluorescent
probe 2 can be used for testing the potency and selectivity of
Figure 2. A) EL4 cell lysate incubated with classical probe HAUbVME
(HAUbVME (expr)) obtained by the conventional intein method, and with
the chemically synthesized, HA-tagged probe 1. Proteins were separated by
SDS-PAGE and analyzed by immunoblotting. Actin, loading control. B) EL4
lysate incubated with fluorescent probe 2. Proteins were separated by SDS-
PAGE and analyzed by in-gel fluorescence scanning.
Figure 3. Affinity pull-down of UCHL3 by using photocleavable probe 5. Pro-
teins were separated by SDS-PAGE and analyzed by Coomassie staining and
by western blotting followed by staining with streptavidin–poly-HRP. Release
of labeled UCHL3 by UV is shown (left panel), whereas photocleavage was
confirmed by the absence of a biotin tag (right panel).
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DUB inhibitors, four compounds were selected that inhibit
DUBs associated with cell growth and tumor progression: b-
AP15,[14] Compound A,[15] PR-619,[9a] and WP1130.[9b,16] The po-
tency of each selected DUB inhibitor was examined in a com-
petitive activity-based assay in which EL4 cell extract was in-
cubated with a range of inhibitor concentrations and subse-
quently labeled with probe 2 (Figures 4 and S12). The resulting
gels display a dose-dependent reduction of probe labeling for
all four inhibitors and all appeared to block a wide panel of
DUBs when using increasing inhibitor concentrations.
Assaying the effect of genetic and cell biological
manipulations on cellular DUB activity
Because fluorescent UbVME probes offer a direct means to
assay DUB activity in cell lysate, they may be utilized to moni-
tor the functional outcomes of genetic and cell biological ma-
nipulations of specific DUBs. USP14 is an abundant DUB that
reversibly associates with the proteasome and trims Ub chains
before substrate degradation. Inhibition of USP14 by the small
molecule IU1 has been shown to enhance proteasome activity,
which has been suggested as a novel therapeutic strategy.[17]
USP14 (~56 kDa) migrates as a 65 kDa fluorescent band once
attached to the probe. MelJuSo cells were treated with a pool
of four siRNA oligos that target USP14 (Figure S13, lane 2), indi-
vidual oligos (Figure S13, lanes 3 and 4) or control siRNA (Fig-
ure S13, lane 1). A decrease in USP14 reactivity with probe 2
reflects loss of functional USP14 from respective lysates. No
appreciable loss of other probe-reactive bands was detected in
the same samples in response to anti-USP14 siRNA.
As with DUB depletion, probe 2 can be used to profile the
activity of DUBs expressed ectopically in their normal cellular
environment, where endogenous post-translational modifica-
tions and spatiotemporal localization are maintained. Further-
more, in combination with standard immunoblotting tech-
niques, probe 2 enabled quantitative assessment of the pro-
portion of reacted enzyme. For instance, in the presence of
probe 2, over-expression of GFP-tagged USP14 yielded an
additional fluorescent band at 90 kDa not observed when
expressing GFP alone, or catalytic point-mutant USP14-C114S
(Figure 5, lanes 3–5, top). Accordingly, immunoblotting for GFP
revealed a shift of approximately 10 kDa for GFP-USP14 in the
presence of probe 2, but not for the C114S mutant (Figure 5,
lanes 1, 4, and 5, anti-GFP IB). Specific inhibition of both en-
dogenous and GFP-tagged USP14 was observed in cells treat-
ed with compound IU1 (Figure 5, lanes 4, 6 and 7),[17a] whereas
reactivity of other abundant endogenous DUBs or over-ex-
pressed GFP-USP8 remained insensitive to IU1 (Figure 5, lanes
9 and 10). Conversely, all probe-reactive bands, including GFP-
USP8, were completely inhibited in the presence of the cys-
teine alkylating agent N-methylmaleimide (NMM, Figure 5,
lanes 2 and 8).
Visualization of differential DUB activity profiles of cancer
cells
Probe 2 also allows a fast and sensitive characterization of dif-
ferential DUB activity patterns, for instance observed in various
Figure 4. EL4 lysate was incubated with the indicated concentrations of
small-molecule DUB inhibitor b-AP15 (top). Subsequently, lysate was labeled
with probe 2. Proteins were separated by SDS-PAGE and the residual DUB
activity was visualized by in-gel fluorescence scanning (bottom).
Figure 5. GFP, GFP-USP14, GFP-USP14 catalytic mutant, and GFP-USP8 were
overexpressed in MelJuSo cells, and lysates were incubated in the absence
or presence of inhibitor IU1 or NMM, before labeling with probe 2. Proteins
were separated by SDS-PAGE before fluorescence scanning or western blot-
ting followed by profiling with the indicated antibodies. Actin, loading con-
trol. IB= immunoblotting.
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cancer cell lines. DUB profiling can be used to identify tumor-
specific DUBs and their inhibitors, thus contributing to the def-
inition of new targets in cancer therapy. In healthy individuals
expression of UCHL1 is limited to neurons and testes,[18] while
overexpression of UCHL1 has been shown in a variety of can-
cers.[19] For example, UCHL1 is markedly expressed in lung
cancer cell lines and primary lung tumors, but not in normal
lung tissue.[20] UCHL1 has recently also been shown to promote
cancer metastasis in prostate cancer cells.[19] The function of
UCHL1 is not fully understood, although UCHL1 has been
shown to enhance invasive potential in vitro and in vivo.[21]
We used probe 2 to visualize the activity of UCHL1 in a
panel of lung and prostate cancer cell lines. In the various lung
cancer cell lines tested, we observed high UCHL1 activity in
cell lines H1299,[22] H460,[23] PC9,[24] and A549,[25] but no UCHL1
activity was observed in cell lines M28 or H358[21a,22] (Fig-
ure 6A), which is consistent with reported literature. In the
prostate carcinoma cell lines we observed high activity of
UCHL1 in VCaP, DU145,[19] and PC3M cells, but no activity in
PC3[24] or LnCap cells[26] (Figures 6B and S14). UCHL1 expres-
sion was confirmed by immunoblotting (Figure S15). Recently,
UCHL1 was demonstrated to contribute to the highly metastat-
ic character of DU145 cells (derived from brain metastatic
sites).[19] Interestingly, we observed high UCHL1 activity in
PC3M cells, a more metastatic variant of the PC3 cell line that
does not display UCHL1 activity, further supporting a link to
metastasis.
Conclusions
We have shown that Ub-based probes can be synthesized
chemically with great ease and in large amounts, and that this
method can be adapted to include modules that fulfill specific
experimental requirements. A great variety of building blocks
can now be easily incorporated into the Ub sequence, such as
natural and unnatural amino acids, fluorescent tags, affinity
handles, spacers, and cleavable linkers. We have demonstrated
that similar labeling patterns are observed when labeling cell
extract with either epitope-tagged probe obtained by intein
chemistry or chemically synthesized epitope-tagged probe. We
could easily incorporate additional affinity handles and selec-
tive cleavage moieties thereby enabling affinity pull-down and
subsequent mild UV-activated release of DUBs. Incorporation
of a fluorescent tag allowed fast direct in-gel fluorescence
scanning, and we have shown that fluorescent UbVME is a sen-
sitive and convenient tool for the rapid profiling of DUB inhibi-
tor potency and specificity. For example, we were able to dem-
onstrate that amongst the five reported DUB inhibitors tested
here, IU1 was selective for USP14, while the other inhibitors
can be regarded as broad-spectrum DUB inhibitors. Genetic
and cell biological manipulation of cellular DUB activity was
successfully tracked by using a fluorescent probe, as illustrated
by the visualization of depletion of USP14 and the overexpres-
sion of GFP-tagged USP14 and USP8. Direct comparison of dif-
ferential DUB activity profiles amongst a panel of cancer cell
lines might find application as a rapid diagnostic tool to pre-
dict the outcome of DUB inhibitor therapy. In conclusion, the
DUB-activity probes reported here constitute an important ad-
dition to the laboratory toolkit in ubiquitin signal transduction
research.
Experimental Section
General: All chemicals used in this study were purchased from Bio-
solve (Valkenswaard, The Netherlands) or Sigma–Aldrich, unless
otherwise indicated, and at the highest commercially available
grade. Peptide building blocks were purchased from Novabiochem
(EMD Millipore) and glycine-functionalized trityl resin (TentaGel R
TRT-Gly Fmoc) from Rapp Polymere (Tbingen, Germany). All
chemicals and solvents were used as received. Cy5,[27] TMR,[28] (E)-
methyl-4-aminobut-2-enoate (GlyVME),[29] inhibitor compound A, b-
AP15[30] and PR-619[9a] were synthesized according to previously es-
tablished methods. Compound WP1130 was purchased from Sell-
eck Chemicals (Houston, TX). Ubiquitin carboxyl-terminal esterase
L3 (UCH-L3) was produced recombinantly according to published
procedures.[31] Preparative HPLC was performed on a Prominence
HPLC system (Shimadzu) equipped with a Atlantis T3 column (10
150 mm, 5 mm; Waters) by using two mobile phases: A (TFA (0.1%)
in water) and B (formic acid (0.1%) in acetonitrile): flow rate,
7.5 mLmin1; run time, 35 min; column temp., 40 8C; gradient: 0–
5 min, 5% B; 5–8 min, !25% B; 8–30 min, !60% B; 30–33 min,
!95% B; 33–35 min, 95% B. Analytical HPLC was performed on
a 1525EF Binary HPLC pump (Waters) equipped with a 2487 Dual
l Absorbance Detector. Samples were run over an Atlantis DC18
column (6.4150 mm, 10 mm; Waters) with two mobile phases: A
(TFA (0.05%) in water) and B (TFA (0.05%) in acetonitrile) ; gradi-
ents: 0–1 min, 1% B; 1–13 min, !90% B; 13–16 min, 90% B; 16–
17 min, !1% B; 17–25 min, 1% B; or 0–5 min, 5% B; 5–30 min, !
95% B; 30–35 min, 95% B; 35–40 min, !5% B; 40–45 min, 5% B.
LC-MS measurements were performed on a system equipped with
a Alliance 2795 Separation Module (Waters), 2996 Photodiode
Array Detector (190–750 nm), and LCT Orthogonal Acceleration
Time of Flight Mass Spectrometer. Samples were run over a kinetix
C18 column (2.150 mm, 2.6 mm; Phenomenex, Torrence, CA),
with flow rate 0.8 mLmin1, runtime 6 min, column temp. 40 8C,
and two mobile phases: A (acetonitrile(1%) and formic acid (0.1%)
in water) and B (water (1%) and formic acid (0.1%) in acetonitrile);
Figure 6. Visualization of DUB activity in cancer cell lines. A) In a panel of
lung cancer cell lines, DUB activity profiles were examined by treating ly-
sates with probe 2. UCHL1 is highly expressed in cell lines A549, H460,
H1299, and PC9. B) In a panel of prostate cancer cell lines probed with 2,
UCHL1 is highly expressed in cell lines VCaP, PC3M, and DU145.
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gradient: 0–0.5 min, 5% B; 0.5–4 min, !95% B; 4–5.5 min, 95% B.
Data processing was performed with MassLynx Mass Spectrometry
Software 4.1 (deconvolution with Maxent1 function; Waters). SDS-
PAGE was performed on 4–12% NuPAGE Novex Bis-Tris Mini-gels
(Invitrogen) and run in MOPS buffer at 170 V, unless stated other-
wise. In-gel fluorescence scans were obtained by using a ProXPRESS
2D Proteomic imaging system (Perkin–Elmer) with a resolution of
100 mm and exposure time of 60 s, with filter settings (lex/lem) 550/
590 nm (TMR) or 625/680 nm (Cy5). Chemiluminescence (ECL west-
ern blotting detection kit; GE Healthcare) was visualized on a
Chemidoc XRS+ System with Image Lab software (Bio-Rad, Her-
cules, CA). Immunoblots stained with fluorescent antibodies were
visualized by using an Odyssey Infrared Imaging System (LI-COR,
Lincoln, NE).
Cell culture: EL4 cells, lung cancer cells M28, A549, PC-9, H358,
H460, and H1299, and prostate cancer cells PC3, PC3M, DU145,
VCaP, and LNCaP were grown in Gibco RPMI 1640 medium (Life
Technologies) supplemented with fetal calf serum (FCS, 10% v/v)
at 37 8C in a 5% CO2 atmosphere. EL4 growth medium was supple-
mented with penicillin (100 UmL1) and streptomycin
(100 mgmL1). The growth medium for the prostate cancer cell
lines was supplemented with l-glutamine (2 mm). MelJuSo cells
were grown in Gibco IMDM medium (Life Technologies) supple-
mented with FCS (10%) at 37 8C in a 5% CO2 atmosphere. Prostate
cancer cell lines PC3, PC3M, DU145, and LNCaP were obtained
from the American Type Culture Collection (Manassas, VA). VCaP
cells were kindly obtained from Dr. Guido Jenster (ECMC Rotter-
dam).
Linear chemical synthesis of active-site directed Ub-based
probes
Method A (for probes 1, 3, 4, and 5): The Ub(1–75) peptide se-
quence with a free N terminus but with side chains protected, was
synthesized (25 mmol scale) on a trityl resin by following Fmoc
solid-phase peptide synthesis procedures as described,[12] with
minor modifications. Briefly, for the first 30 cycles, couplings were
performed in N-methylpyrrolidone (NMP) for 40 min by using
PyBOP (4 equiv), N,N-diisopropylethylamine (DIPEA) (8 equiv), and
protected amino acid (4 equiv). Fmoc protecting groups were
removed by treating the resin with piperidine (20%) in NMP (2
3 min and 15 min). For Leu43, Lys48, Leu50, and Glu51, double
coupling was applied (240 min). For cycles 31–40, the coupling
time was extended to 60 min and double couplings were applied
for Asp32, Lys33, Pro 37, and Pro38. Fmoc deprotection was per-
formed by using piperidine (20%) in NMP (43 min). After
cycle 40, double couplings were performed for all amino acids.
Pseudoproline building blocks Fmoc-l-Leu–l-Thr(YMe,Mepro)-OH
(replacing Leu8–Thr9), Fmoc-l-Ile–l-Thr(YMe,Mepro)-OH (replacing
Ile13–Thr14), Fmoc-l-Leu–l-Ser(YMe,Mepro)-OH (replacing Leu56–
Ser57), Fmoc-l-Ser(tBu)–l-Thr(YMe,Mepro)-OH (replacing Ser65–
Thr66), and Dmb dipeptides Fmoc-l-Ala–(Dmb)Gly-OH (replacing
Ala46–Gly47) and Fmoc-l-Asp(OtBu)–(Dmb)Gly-OH (replacing
Asp52–Gly53) were coupled by using single couplings for 90 min.
The N-acetyl capping steps that we applied in previous synthe-
ses[12] were omitted here. Double couplings were applied for the
Fmoc-protected amino acids of the HA-tag and His6-tag. Carboxy-
functionalized Cy5, biotin, or Fmoc-protected Ahx linker (Fmoc-
Ahx-OH), Fmoc-protected 3-amino-3-(2-nitrophenyl) propionic acid
(Fmoc-Anp-OH) or Fmoc-protected lysine-containing biotin cou-
pled to the e amine (Fmoc-Lys(Biotin)-OH; Figure S2) were coupled
to the N terminus of Ub on resin by using building block (4 equiv),
benzotriazol-1-yl-oxytripyrrolidinophosphium hexafluorophosphate
(PyBOP; 4 equiv), and DIPEA (8 equiv) in NMP at ambient tempera-
ture for 16 h. Fmoc groups were removed as described.[12] N-termi-
nally functionalized Ub conjugates were removed from the resin
by using 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) as described.[12]
Gly-VME (10 equiv) was coupled to the C terminus of Ub by using
PyBOP (5 equiv), triethylamine (Et3N) (20 equiv) in DCM (5 mL) and
stirred for 16 h at ambient temperature. Excess Gly-VME was re-
moved by washing the DCM solution with 1m KHSO4. The organic
layer was dried with Na2SO4 and concentrated to dryness in vacuo.
To remove the side-chain protecting groups, the residue was taken
up in trifluoroacetic acid/triisopropylsilane/water (5 mL; 95:2.5:2.5)
and stirred for 3 h at ambient temperature. The reaction mixture
was added to a falcon tube containing ice-cold pentane/diethyl
ether (1:3; 40 mL), upon which the product precipitated. The pre-
cipitate was isolated by centrifugation (1500g, 6 min, 4 8C) and
washed by three cycles of resuspension in ice-cold diethyl ether
and centrifugation. Finally, the pellet was taken up in water/aceto-
nitrile/acetic acid (65:25:10), frozen, and lyophilized.
Method B (for probe 2): As TMR contains two carboxylic acid
groups, subsequent coupling of GlyVME to the peptide would lead
to the attachment of two GlyVME moieties, one at the C terminus
and one at the TMR carboxylate. To prevent this, Ub(1–75) with
a free N terminus but protected side chains was cleaved from the
resin by using HFIP as described,[12] and GlyVME was coupled to
the C terminus in solution as described above, before condensa-
tion of TMR (4 equiv) to the N terminus, by using PyBOP (4 equiv)
and DIPEA (10 equiv) in DCM (5 mL), and stirring for 16 h at ambi-
ent temperature. The reaction mixture was concentrated to dry-
ness in vacuo. Removal of side chain protecting groups was per-
formed as for Method A.
All resulting probes were subsequently purified by preparative
HPLC. For further applications, probes were dissolved (to 25 mm) in
sodium acetate buffer (50 mm, pH 4.5) containing DMSO (5%).
Liquid chromatography profiles and mass spectra of all probes syn-
thesized are shown in Figures S3–S9.
Preparation of cell extracts and labeling with Ub-based probes:
Cells were lysed by sonication in lysis buffer (Tris (50 mm), sucrose
(250 mm), MgCl2 (5 mm), DTT (1 mm)) supplemented with CHAPS
(0.5%) and NP40 (0.1%), and clarified by spinning (16000g,
10 min, 4 8C). For lysis of prostate cancer cell lines 1 Complete
Protease Inhibitor Cocktail (Roche) was added to the lysis buffer.
Typically, labeling experiments were performed in lysis buffer
(25 mL) containing protein extract (1 mgmL1) and Ub-based probe
(1 mm), unless otherwise indicated. The pH was neutralized by
adding NaOH (50 mm, 2 equiv (v/v) relative to probe). Labeling re-
actions were incubated for 30 min at ambient temperature before
being terminated by addition of reducing sample buffer and heat-
ing (70 8C, 10 min). Activity-based protein profiling of DUB inhibi-
tors was performed in the presence of DMSO (5%). Extracts were
preincubated with compound at the indicated concentrations and
times, before the addition of probe and a further incubation for
15 min at ambient temperature. Proteins were resolved by SDS-
PAGE. Following in-gel fluorescence scanning, gels were transferred
onto PVDF membranes (1 h, 15 V) and blotted by using mouse
anti-HA (12A5; Roche), mouse anti-b-actin (Sigma–Aldrich), or
streptavidin–poly-HRP (Sanquin, Amsterdam, the Netherlands).
Where necessary, HRP-conjugated rabbit anti-mouse was used as
a secondary antibody (P0161; Dako, Glostrup, Denmark), and im-
munoblots were visualized by chemiluminescence. Alternatively,
gels were transferred onto nitrocellulose membranes (1 h, 15 V)
and blotted with rabbit anti-HA (Sigma–Aldrich) and mouse anti-b-
actin (Sigma–Aldrich) in combination with fluorescent secondary
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antibodies goat anti-mouse IRDye 680LT and goat anti-rabbit-IRDye
800CW (LI-COR), and visualized by fluorescence scanning.
Affinity pull-down and photoactivated release of UCH-L3: In buf-
fer A (40 mL, phosphate buffer (100 mm, pH 7.1), NaCl (150 mm))
containing DMSO (2.5%), UCH-L3 (25 mg) was incubated with
probe 5 (25 mm) for 1 h at 37 8C. The reaction mixture was added
to buffer A (30 mL) and High Capacity Neutravidin resin (20 mL,
Thermo Scientific) that was washed (5) with buffer A (100 mL),
and incubated for 3.5 h at 37 8C. The beads were washed exten-
sively with buffer A (5 70 mL) and buffer B (Tris·HCl (50 mm,
pH 7.0), NaCl (300 mm), SDS (1%); 470 mL). Beads were taken up
in buffer A (70 mL) containing DTT (1 mm), and transferred to a 96-
well plate (Black Flat Bottom Polystyrene, nonbinding surface;
Corning, Corning, NY). The plate was shaken at 4 8C for 1 h while
exposed to UV (365 nm, 15 W; Uvitec, Cambridge, UK). Input, flow
through, and elution samples were resolved by reducing SDS-PAGE
(12%, MES). One gel was stained with Coomassie, while a duplicate
gel, run simultaneously, was used for blotting with streptavidin–
poly-HRP as described above.
Genetic and cell biological manipulations affecting cellular DUB
activity: Knockdown of USP14 in MelJuSo cells was achieved by
using either a pool of four siGENOME oligonucleotides or individu-
al oligos siUSP14-1 (GCAUA UCGCU UACGU UCUA) or siUSP14-2
(GGAGU UACCA UGUGG AUUG; Dharmacon/Thermo Scientific) at
a final concentration of 50 nm, delivered by transient transfection
with DharmaFECT 4 (Dharmacon) according to manufacturer’s in-
structions. Cells were grown in Falcon six-well tissue culture plates
(BD Biosciences). Samples were harvested 72 h following transfec-
tion by scraping on ice in lysis buffer (100 mL). Lysates were briefly
sonicated and clarified (10000 rpm, 10 min, 4 8C). Lysate prepara-
tion (1.87 mgmL1) in lysis buffer (30 mL) was incubated with
probe 2 (1.67 mm) for 15 min at ambient temperature. Reactions
were terminated, and samples were resolved by SDS-PAGE and an-
alyzed as described above.
For overexpression of GFP-tagged DUBs in cells, wild type USP14
was subcloned from pDEST-USP14 (Addgene, Cambridge, MA) into
eGFP-C1 vector (Clontech, Mountain View, CA) at XhoI/EcoRI re-
striction sites by using standard protocols. Mutagenesis (C114S) to
generate a catalytically inactive USP14 was performed according to
standard protocols by using TurboPfu DNA polymerase (Strata-
gene/Agilent Technologies) with the forward (CTT GGT AAC ACT
TCT TAC ATG AAT GCC) and reverse (GGC ATT CAT GTA AGA AGT
GTT ACC AAG) primers (Invitrogen/Life Technologies). The GFP-
USP8 construct was generously provided by Dr. Sylvie Urb (Uni-
versity of Liverpool, UK). DNA delivery into MelJuSo cells was per-
formed in 60 mm tissue culture plates by using Lipofectamine2000
(Invitrogen) according to manufacturer’s instructions. Samples
were harvested 24 h following transfection in buffer (0.25 mL), and
lysates were prepared as indicated above. DMSO alone or with dis-
solved inhibitors was added to lysis buffer (10 mL) supplemented
with CHAPS (0.5%) and NP40 (0.1%) (DMSO <6% of total reaction
volume) and mixed with lysate preparation (20 mL). Final inhibitor
concentrations were: N-methyl maleimide (NMM) 4 mm, IU1
100 mm. Samples were incubated for 30 min at ambient tempera-
ture, and probe 2 (2 mL, 25 mm) was then added for 5 min at ambi-
ent temperature. Samples were analyzed as described above. Fol-
lowing fluorescence scanning, gels were transferred onto nitrocel-
lulose membranes (2 h, 300 mA) and immunoblotted with rabbit
anti-GFP serum[32] and mouse anti-b-actin (Sigma–Aldrich) in com-
bination with fluorescent secondary antibodies (goat anti-mouse
IRDye 680LT and goat anti-rabbit IRDye 800CW, LI-COR). Immuno-
blots were visualized by fluorescence scanning.
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